A combination of empagliflozin and curcumin reduced liver inflammation by over 70% in mice fed high-fat diets, working significantly better together than either substance alone. According to Gram Research analysis, the combination shifted harmful immune cells toward protective types and reduced inflammatory signaling, suggesting a promising future treatment approach for fatty liver disease—though human studies are still needed.
Researchers discovered that combining two substances—empagliflozin (a diabetes medication) and curcumin (a compound from turmeric)—works better together than separately to reduce liver inflammation caused by high-fat diets. In a study with mice, the combination dramatically reduced harmful immune cells in the liver and switched inflammatory cells from a damaging type to a protective type. According to Gram Research analysis, this finding suggests a promising new approach for treating metabolic dysfunction-associated steatotic liver disease (fatty liver disease), a condition affecting millions of people worldwide.
Key Statistics
A 2026 animal study of 50 mice found that combining empagliflozin and curcumin reduced hepatic macrophage infiltration and inflammatory markers by over 70% compared to high-fat diet alone, with effects significantly more pronounced than either treatment individually (p < 0.001).
Research published in the Journal of Diabetes and Metabolic Disorders showed that the empagliflozin-curcumin combination shifted liver immune cells from a pro-inflammatory M1 phenotype to a protective M2 phenotype while reducing NF-κB p65 expression, the master switch controlling inflammatory genes.
In a 23-week mouse study, co-administration of empagliflozin and curcumin produced significantly greater reductions in pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) compared to either agent alone in high-fat diet-induced fatty liver disease.
The Quick Take
- What they studied: Whether combining empagliflozin (a diabetes drug) with curcumin (turmeric extract) could reduce liver inflammation better than using either substance alone in mice fed high-fat diets.
- Who participated: Male laboratory mice (C57BL/6J strain) divided into 5 groups of 10 mice each, fed different diets for 23 weeks: normal diet, high-fat diet, or high-fat diet with various treatments.
- Key finding: The combination treatment reduced liver inflammation markers by over 70% compared to high-fat diet alone, and worked significantly better than either treatment by itself (p < 0.001, meaning the results were very unlikely to happen by chance).
- What it means for you: This research suggests a potential new treatment strategy for fatty liver disease, but these are early-stage mouse studies. Human trials would be needed before doctors could recommend this combination to patients. If you have fatty liver disease, talk to your doctor about proven treatments while researchers continue studying this approach.
The Research Details
Scientists used laboratory mice to test whether combining two substances could reduce liver inflammation caused by eating a high-fat diet. They divided 50 mice into five groups: one group ate a normal diet (the healthy control), and four groups ate a high-fat diet with different treatments—no treatment, empagliflozin alone, curcumin alone, or both substances together. All mice were observed for 23 weeks while eating their assigned diets.
After 23 weeks, researchers examined the livers of all mice using several methods. They used special staining techniques to count immune cells in the liver tissue, measured levels of inflammatory chemicals in the blood, and analyzed how genes related to inflammation were turned on or off. They also looked at liver tissue under a microscope to see the physical damage caused by the high-fat diet.
This type of study is called a preclinical animal study, which is an important first step in drug development. Animal studies help researchers understand how treatments work at a biological level before testing them in humans. However, results in mice don’t always translate directly to humans, so this research represents early-stage evidence.
Understanding how these two substances work together is important because fatty liver disease is becoming increasingly common worldwide, especially in people with obesity and diabetes. Current treatment options are limited, so finding new combinations that work better than single treatments could lead to better medical options. This study helps explain the biological mechanisms—the actual processes in the body—that make the combination effective, which is crucial for developing safe and effective treatments.
This study has both strengths and limitations. Strengths include the use of a well-established mouse model of fatty liver disease, multiple measurement methods to assess inflammation, and clear statistical analysis. Limitations include the small sample size (10 mice per group), the fact that results are from mice rather than humans, and the relatively short study duration. The study was published in a peer-reviewed journal, meaning other experts reviewed the methods and findings before publication.
What the Results Show
The high-fat diet caused significant liver inflammation in untreated mice, including increased numbers of inflammatory immune cells (macrophages) in the liver tissue. When researchers treated these mice with empagliflozin alone or curcumin alone, they saw partial improvements—both substances reduced inflammation somewhat, but neither completely reversed the damage.
When mice received both substances together, the results were dramatically better. The combination reduced the number of inflammatory immune cells in the liver by more than 70% compared to untreated high-fat diet mice. More importantly, the combination changed the type of immune cells present—it shifted them from a pro-inflammatory type (called M1 macrophages, which cause damage) to an anti-inflammatory type (called M2 macrophages, which help repair damage).
The combination also reduced levels of inflammatory chemicals in the blood, including TNF-α, IL-6, and IL-1β—all substances that contribute to liver damage. Additionally, the treatment reduced activity of a key inflammatory pathway called NF-κB, which is like a master switch that turns on many inflammatory genes. These effects were significantly stronger with the combination than with either treatment alone (p < 0.001).
Histological examination (looking at liver tissue under a microscope) showed that the combination treatment also reduced fat accumulation in liver cells and decreased overall tissue damage compared to the high-fat diet group. The combination appeared to preserve liver structure better than either single treatment. These secondary findings support the primary inflammation measurements and suggest the treatment may have broader protective effects on liver health beyond just reducing inflammatory cells.
Previous research has shown that both empagliflozin and curcumin have individual anti-inflammatory effects, but this is one of the first studies to systematically examine their combined effects on liver inflammation. The finding that the combination works better than either substance alone (called a synergistic effect) is consistent with emerging research suggesting that combining treatments targeting different inflammatory pathways may be more effective than single-agent approaches. This aligns with current trends in treating complex diseases like fatty liver disease.
This study has several important limitations. First, it was conducted in mice, not humans, so the results may not directly apply to people. Second, the sample size was relatively small (10 mice per group), which limits statistical power. Third, the study only lasted 23 weeks, which is relatively short for understanding long-term effects. Fourth, the study didn’t examine potential side effects or optimal dosing for humans. Finally, the study didn’t test whether the benefits persist after stopping treatment or whether tolerance develops over time. These limitations mean this research represents an early-stage finding that requires further investigation before clinical application.
The Bottom Line
Based on this research, we cannot yet recommend empagliflozin and curcumin combination therapy for fatty liver disease in humans. The evidence is preliminary (animal study only). However, this research suggests the combination warrants further investigation in human clinical trials. Current evidence-based recommendations for fatty liver disease include weight loss, regular exercise, reducing refined carbohydrates, and limiting alcohol—all of which have strong human evidence. If you have fatty liver disease, discuss these proven approaches with your doctor.
This research is most relevant to researchers studying fatty liver disease, pharmaceutical companies developing new treatments, and people with metabolic dysfunction-associated steatotic liver disease (MASLD) or non-alcoholic fatty liver disease (NAFLD) who are interested in emerging treatments. People with obesity, type 2 diabetes, or metabolic syndrome should be aware of this research as it may eventually lead to new treatment options. However, this is not yet a treatment recommendation for any patient population.
In this mouse study, significant improvements appeared after 23 weeks of continuous treatment. If this research leads to human trials, it would likely take 5-10 years before any new combination therapy could be available to patients. Even then, it would need to be proven safe and effective in humans before doctors could prescribe it. People with fatty liver disease should focus on proven interventions (diet, exercise, weight loss) while waiting for research to advance.
Frequently Asked Questions
Can I take empagliflozin and curcumin together to treat fatty liver disease?
Not yet based on human evidence. This research is from mice only. While the combination showed promise in animal studies, human clinical trials are needed before doctors can recommend it. Talk to your doctor about proven treatments like weight loss, exercise, and dietary changes, which have strong evidence in humans.
What is macrophage polarization and why does it matter for liver health?
Macrophages are immune cells that can either damage tissue (M1 type) or help repair it (M2 type). In fatty liver disease, harmful M1 macrophages accumulate and cause inflammation. The study showed the combination treatment switched these cells toward the protective M2 type, reducing liver damage and inflammation.
How long would it take for this treatment to work if it becomes available?
In mice, significant improvements appeared after 23 weeks of continuous treatment. If human trials confirm effectiveness, it would likely take 5-10 years before becoming available to patients. Even then, benefits would depend on individual factors like diet, exercise, and overall health.
Is curcumin from turmeric supplements effective for fatty liver disease?
While this study suggests curcumin has anti-inflammatory potential, the evidence in humans is limited. Turmeric supplements alone showed only partial benefits in this mouse study. Proven approaches for fatty liver disease include weight loss, regular exercise, reducing refined carbohydrates, and limiting alcohol.
What does NF-κB do and why is reducing it important?
NF-κB is a master switch that turns on many inflammatory genes in cells. When activated, it triggers production of harmful inflammatory chemicals. The study showed the combination treatment reduced NF-κB activity, which helps explain why inflammation decreased and liver damage was reduced.
Want to Apply This Research?
- Track liver health markers if you have fatty liver disease: monitor weight weekly, record exercise minutes daily, and note any symptoms like fatigue or abdominal discomfort. If your doctor orders liver function tests, log the results (ALT, AST, and GGT enzyme levels) to track changes over time.
- If interested in curcumin-rich foods while awaiting further research, add turmeric to meals 3-4 times weekly (curries, soups, rice dishes). Simultaneously, focus on proven fatty liver interventions: aim for 150 minutes of moderate exercise weekly, reduce added sugars, and work toward a 5-10% weight loss if overweight. Log these behaviors in your app to maintain consistency.
- Create a monthly dashboard tracking: weight, exercise frequency, dietary improvements (especially turmeric intake if you choose to add it), and any changes in energy levels or digestive symptoms. Share this data with your doctor at regular checkups. Set reminders to revisit this research annually as new human studies emerge, and discuss with your healthcare provider whether any new evidence changes your treatment approach.
This research is from an animal study in mice and has not been tested in humans. The findings do not constitute medical advice or a treatment recommendation. Fatty liver disease is a serious condition that requires professional medical evaluation and management. Do not start, stop, or change any medications or supplements without consulting your healthcare provider. If you have fatty liver disease or suspect you might, work with a qualified physician to develop an evidence-based treatment plan. Current proven approaches include weight loss, regular physical activity, dietary modifications, and management of underlying conditions like diabetes and obesity. This article is for educational purposes only and should not replace professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.